Cart
sales@molnova.com
Theliatinib
CAS No. 1353644-70-8
Theliatinib( —— )
Catalog No. M20712 CAS No. 1353644-70-8
Theliatinib a potent and highly selective EGFR inhibitor with anti-tumor activity. Ki of 0.05 nM for wild type EGFR and IC50s of 3 and 22 nM for EGFR and EGFR T790M/L858R mutant respectively.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 164 | In Stock |
|
| 10MG | 268 | In Stock |
|
| 25MG | 442 | In Stock |
|
| 50MG | 656 | In Stock |
|
| 100MG | 888 | In Stock |
|
| 200MG | Get Quote | In Stock |
|
| 500MG | Get Quote | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameTheliatinib
-
NoteResearch use only, not for human use.
-
Brief DescriptionTheliatinib a potent and highly selective EGFR inhibitor with anti-tumor activity. Ki of 0.05 nM for wild type EGFR and IC50s of 3 and 22 nM for EGFR and EGFR T790M/L858R mutant respectively.
-
DescriptionTheliatinib a potent and highly selective EGFR inhibitor with anti-tumor activity. Ki of 0.05 nM for wild type EGFR and IC50s of 3 and 22 nM for EGFR and EGFR T790M/L858R mutant respectively.(In Vivo):Theliatinib (2-15 mg/kg; oral administration;daily; for 21 days; NOD-SCID mice; PDECX 1T0950 model) treatment demonstrates tumor regression of 75% at the end of study, and with a dose response.
-
In Vitro——
-
In VivoTheliatinib (2-15 mg/kg; oral administration;daily; for 21 days; NOD-SCID mice; PDECX 1T0950 model) treatment demonstrates tumor regression of75% at the end of study, and with a dose response. Animal Model:NOD-SCID mice injected with esophageal cancer cells (PDECX 1T0950 model)Dosage:2 mg/kg, 5 mg/kg, 15 mg/kg Administration:Oral administration;daily; for 21 days Result:Attenuated tumor growth in PDECX 1T0950 model in a dose-dependent manner.
-
Synonyms——
-
PathwayAngiogenesis
-
TargetEGFR
-
RecptorEGFR
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1353644-70-8
-
Formula Weight442.5
-
Molecular FormulaC25H26N6O2
-
Purity>98% (HPLC)
-
SolubilityDMSO:47 mg/mL (106.21 mM)
-
SMILES[H][C@]12CCN(C)[C@@]1([H])CN(C2)C(=O)Nc1cc2c(Nc3cccc(c3)C#C)ncnc2cc1OC
-
Chemical Name(3aR6aR)-N-(4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)-1-methylhexahydropyrrolo[34-b]pyrrole-5(1H)-carboxamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Ren Y Zheng J Fan S et al. Anti-tumor efficacy of theliatinib in esophageal cancer patient-derived xenografts models with epidermal growth factor receptor (EGFR) overexpression and gene amplification.[J]. Oncotarget 2017 8(31):50832-50844.
molnova catalog
related products
-
Naquotinib
Naquotinib (ASP-8273) is a potent, irreversible, mutant-selective inhibitor of EGFR.
-
PD 089828
PD 089828 is a competitive inhibitor of the receptor tyrosine kinases FGFR1, PDGFRβ, and EGFR (IC50s = 0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of the nonreceptor tyrosine kinase c-Src (IC50 = 0.18 μM)
-
EMI1
EMI1 can be used in the mutant EGFR-associated, drug-resistant non-small-cell lung cancer(NSCLC) research. EMI1 is an inhibitor of EGFR L858R/T790M/C797S and EGFR ex19del/T790M/C797S .
